Combination of amino acid solution and a gelatin derivative for inhibiting renal up-take
The invention relates to a combination of a solution of a gelatin derivative and at least one amino acid, if desired in the form of a pharmaceutically acceptable salt or carboxylic acid derivative, for inhibiting renal uptake of substances, that are potentially damaging for the kidneys, in a living being.
1. A therapeutic composition for the inhibition of renal uptake of substances that are potentially damaging for the kidneys and that are used for therapeutic or diagnostic purposes in a living being, comprising:
a solution of a gelatin derivative;
at least one amino acid; and
at least one of a pharmaceutically acceptable excipient, carrier, diluent, and combinations thereof.
2. The composition of claim 1 , wherein the composition includes a first quantity of the first amino acid in a range of about 150 milligrams to about 700 milligrams per kilogram body weight of a living being, and a second quantity of the gelatin derivative in a range of about 50 milligrams to about 250 milligrams per kilogram body weight of a living being.
3. The composition of claim 1 , wherein the first amino acid is a lysine selected from the group consisting of D-lysine, L-lysine and polylysine.
4. The composition of claim 1 , wherein the first amino acid is a lysine, wherein the composition further comprises a second amino acid selected from the group consisting of arginine and ornithine.
5. A method of preparing a composition for inhibiting renal uptake of a substance in a living being, comprising:
combining a solution of a gelatin derivative with at least one amino acid.
6. The method of claim 5 , wherein the at least one amino acid is in the form of a pharmaceutically acceptable salt or carboxylic acid derivative.
7. The method of claim 5 , wherein the at least one amino acid is a lysine selected from the group consisting of D-lysine, L-lysine, and polylysine.
8. The method of claim 5 , wherein the at least one amino acid is a mixture of a lysine and a second amino acid selected from the group consisting of arginine and ornithine.
9. The method of claim 5 , wherein the gelatin derivative is a gelatin-based plasma expander.
10. The method of claim 9 , wherein the gelatin-based plasma expander is GELOFUSINE®.
11. The method of claim 5 , wherein the gelatin derivative is a synthetic colloidal solution of urea cross-linked degraded gelatin.
12. The method of claim 11 , wherein the synthetic colloidal solution of urea cross-linked degraded gelatin is HAEMACCEL®.
13. The method of claim 5 , wherein the composition includes a first quantity of the at least one amino acid in a range of about 150 milligrams to about 700 milligrams per kilogram body weight of the living being, and a second quantity of the gelatin derivative in a range of about 50 milligrams to about 250 milligrams per kilogram body weight of the living being.
14. The method of claim 5 , further comprising combining at least one of a pharmaceutically acceptable excipient, carrier, diluent, and combinations thereof with the combination of the solution of the gelatin derivative and the at least one amino acid.
15. A method of inhibiting renal uptake of a substance in a living being, comprising:
preparing a composition, wherein the composition includes:
a solution of a gelatin derivative; and
a first amino acid, wherein the first amino acid is in the form of a pharmaceutically acceptable salt or carboxylic acid derivative; and
administering the composition to the living being.
16. The method of claim 15 , wherein the first amino acid is a lysine selected from the group consisting of D-lysine, L-lysine and polylysine.
17. The method of claim 15 , wherein the first amino acid is a lysine, wherein the composition further comprises a second amino acid selected from the group consisting of arginine and ornithine.
18. The method of claim 15 , wherein the gelatin derivative is a gelatin-based plasma expander.
19. The method of claim 18 , wherein the gelatin-based plasma expander is GELOFUSINE®.
20. The method of claim 15 , wherein the gelatin derivative is a synthetic colloidal solution of urea cross-linked degraded gelatin.
21. The method of claim 20 , wherein the synthetic colloidal solution of urea cross-linked degraded gelatin is HAEMACCEL®.
22. The method of claim 15 , wherein the composition includes a first quantity of the first amino acid in a range of about 150 milligrams to about 700 milligrams per kilogram body weight of the living being, and a second quantity of the gelatin derivative in a range of about 50 milligrams to about 250 milligrams per kilogram body weight of the living being.
23. The method of claim 15 , wherein the composition further comprises at least one of a pharmaceutically acceptable excipient, carrier, diluent, and combinations thereof.
24. The composition of claim 1 , wherein the gelatin derivative is a gelatin-based plasma expander.